TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10591433
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (20-40 microg)
Study: 2261147
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 to 40 mg/day)
Study: 6360297
Drug: Stamey-type bladder
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stamey-type bladder neck suspension
Study: 30409409
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion (500mg.day‐1 for 21 days)
Study: 30409409
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion (0.5μg.kg‐1.min‐1 for 21 days)
Study: 29509598
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol in softgel capsules
Study: 25095322
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg/kg (M1)
Study: 25095322
Drug: Ketamine 5
Normalized name: ketamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 5 mg/kg (K1)
Study: 22257365
Drug: SRA+G (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA+G (Standard Risk Assessment with Genetic Testing)
Study: 22257365
Drug: All arms
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All arms (SRA+G, SRA, No-test)
Study: 14520944
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g/day) and clarithromycin (0.5 g/day) for 10 days along with omeprazole (40 mg/day)
Study: 14520944
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg/day) only
Study: 8799523
Drug: bretazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bretazenil (0.5 mg) + alcohol
Study: 8799523
Drug: diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (10 mg) + alcohol
Study: 8799523
Drug: bretazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bretazenil (0.5 mg)
Study: 6723769
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine with 11 g aluminium phosphate
Study: 6723769
Drug: Prednisolone with
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone with 11 g aluminium phosphate
Study: 29939885
Drug: Polyhexamethylene biguanide
Normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexamethylene biguanide (PHMB) solution
Study: 28473423
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg subcutaneously weekly for 24 weeks
Study: 23131717
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab injections monthly for 3 doses
Study: 12700373
Drug: Paclitaxel-eluting stent
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-eluting stent (high dose, 3.1 microg per square millimeter)
Study: 12700373
Drug: Paclitaxel-eluting stent
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-eluting stent (low dose, 1.3 microg per square millimeter)
Study: 10839292
Drug: Chemotherapy (fluoropyrimidine-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (fluoropyrimidine-based, various routes and schedules)
Study: 10839292
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (observation or supportive care)
Study: 31094482
Drug: Mertenil® at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mertenil® at initial dosage of 10 mg/day (Scheme I)
Study: 31094482
Drug: Ekvamer® 5/10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ekvamer® 5/10/10 mg/day (Scheme II)
Study: 31094482
Drug: Mertenil® 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mertenil® 10 mg/day + Ekvator® 5/10 mg/day (Scheme III)
Study: 31094482
Drug: Fenofibrate intake
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate intake in a dose of 145 mg/day (for TG >2.3 mmol/l)
Study: 27499527
Drug: Systematic oral
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic oral care by the researcher
Study: 27499527
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care by nurses (Control)
Study: 24810310
Drug: HMB, arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB, arginine and glutamine mixture alongside oral nutritional supplements (n=11)
Study: 24810310
Drug: Standard nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutritional care alongside oral nutritional supplements (n=12)
Study: 17334592
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist (leuprolide acetate 7.5 mg/month)
Study: 17334592
Drug: Antiandrogen monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen monotherapy (bicalutamide 50 mg q.d., nilutamide 150 mg t.i.d., flutamide 250 mg t.i.d.)
Study: 15527426
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (white light, 10,000 lux, 1 h daily)
Study: 15527426
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (red light, 50 lux, 30 min daily)
Study: 9277070
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.3 mg/kg/d) + Flucytosine (150 mg/kg/d) + Itraconazole (400 mg/d)
Study: 31090337
Drug: Modified Buyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Buyang Huanwu Decoction (in addition to rt-PA intravenous thrombolysis)
Study: 31090337
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rt-PA intravenous thrombolysis only)
Study: 29024233
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of low-dose aspirin (LDA) plus 4100 U of low molecular weight heparin (LMWH) subcutaneously daily
Study: 29024233
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of low-dose aspirin (LDA) alone
Study: 29024233
Drug: Persistently abnormal
Normalized name: BD Persist
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistently abnormal D-dimer or increased D-dimer after treatment
Study: 18574553
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil administered on hemodialysis day (HD day group)
Study: 18574553
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil administered on non-dialysis day (non HD day group)
Study: 15352911
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction interferon-alpha2b (5 million units daily for 4 weeks) followed by standard dose therapy (3 million units three times a week for 44 weeks for genotype 1 or 20 weeks for non-genotype 1)
Study: 15352911
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose therapy (3 million units three times a week for total treatment duration)
Study: 10404791
Drug: No hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormonal replacement therapy (Control)
Study: 7550205
Drug: Postural drainage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postural drainage and manual chest percussion (Treatment A)
Study: 7550205
Drug: Breathing through
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing through a commercial device with oscillating positive expiratory pressure (Treatment B)
Study: 6987028
Drug: Metoprolol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (single oral doses of 25, 50, 75, 100, or 150 mg)
Study: 6987028
Drug: Metoprolol (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (multiple doses at 25, 50, or 100 mg thrice daily)
Study: 27761980
Drug: Lactobacillus gasseri
Normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus gasseri CP2305 administered daily for 4 weeks
Study: 25833666
Drug: Pharmacist medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist medication review with face-to-face pharmacist prescribing
Study: 25833666
Drug: Pharmacist medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist medication review with feedback to general practitioner
Study: 21054515
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO), dosage and duration not specified
Study: 19824054
Drug: SFC (salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (salmeterol 50 microg/FP 100 microg twice daily)
Study: 19824054
Drug: FP (fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP (fluticasone proprionate 200 microg twice daily)
Study: 10952772
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (Gem Vin) at dose level I (1000/25 mg/m(2))
Study: 10952772
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (Gem Vin) at dose level II (1200/25 mg/m(2))
Study: 10952772
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (Gem Vin) at dose level III (1000/30 mg/m(2))
Study: 9002810
Drug: HEMA‐glutaraldehyde bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEMA‐glutaraldehyde bonding agent
Study: 9002810
Drug: formamide‐containing bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: formamide‐containing bonding agent
Study: 6238209
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (MPA) therapy
Study: 3539830
Drug: Biostim (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostim (8 mg daily)
Study: 3539830
Drug: Biostim (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostim (2 mg daily)
Study: 24874316
Drug: Cortexin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin (10 mg three times a day intramuscularly, two courses)
Study: 24874316
Drug: Cortexin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortexin (10 mg three times a day intramuscularly, one course)
Study: 15720087
Drug: 585 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585 nm pulsed-dye laser (single treatment)
Study: 15720087
Drug: 585 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585 nm pulsed-dye laser (double treatment)
Study: 15720087
Drug: Control (periorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (periorbital region without treatment)
Study: 12882865
Drug: Hyperbaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation (HBO) therapy, applied twice a day, 5 days a week for 2 weeks, each session lasting 90 min at 2.5 ATA.
Study: 12882865
Drug: Hyperbaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation (HBO) therapy
Study: 10959507
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment protocol (LTP) with 60 microg PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no drugs for 3 months.
Study: 10959507
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment protocol (STP) with 20 microg on the first day, 40 microg in the afternoon, and 60 microg on the second day, then 60 microg bid for subsequent cycles.
Study: 8648221
Drug: Subvirion trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion trivalent influenza vaccine
Study: 1465038
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms oestradiol administered as vaginal pessaries daily for 3 weeks prior to surgery
Study: 1465038
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as vaginal pessaries daily for 3 weeks prior to surgery
Study: 27595110
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing 3% ethanolic extract of Brazilian green propolis (EEP-B)
Study: 27595110
Drug: Gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel without EEP-B
Study: 27595110
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing EEP-B
Study: 24744316
Drug: 25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/d RM + 25 g of maltodextrin/d
Study: 24744316
Drug: 50 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/d RM + 0 g/d maltodextrin
Study: 24744316
Drug: 0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/d RM + 50 g/d maltodextrin (placebo)
Study: 24744316
Drug: 25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/d RM
Study: 24744316
Drug: 50 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/d RM
Study: 20167145
Drug: BUD/FM pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM pMDI 160/9 micrograms twice daily (320/18 micrograms daily)
Study: 20167145
Drug: BUD/FM pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM pMDI 320/9 micrograms once daily (evening)
Study: 20167145
Drug: BUD/FM pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM pMDI 160/9 micrograms once daily (evening)
Study: 20167145
Drug: BUD pMDI
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD pMDI 320 micrograms once daily (evening)
Study: 16412352
Drug: Vitamin K(1)
Normalized name: vitamin K 1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K(1) group (10 mg per day for 2 to 7 days, antenatal administration)
Study: 16412352
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin K(1) treatment)
Study: 8645026
Drug: Anti-emetic administration
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-emetic administration group
Study: 8645026
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration group
Study: 1463154
Drug: i.v. midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. midazolam (17 patients; 2.85 +/- 0.84 mg)
Study: 1463154
Drug: sublingual flunitrazepam
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual flunitrazepam (16 patients; 0.005 mg/kg)
Study: 24953293
Drug: Rush oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rush oral immunotherapy (OIT) with peanuts, ingested 3-5 times a day every 30 minutes, increasing the dose by 20% each time, goal dose 3.5-7 g
Study: 22706327
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg twice daily
Study: 20148372
Drug: Albuterol plus
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol plus caffeine placebo
Study: 20148372
Drug: Albuterol with
Normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol with 3 mg/kg caffeine
Study: 20148372
Drug: Albuterol with
Normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol with 6 mg/kg caffeine
Study: 20148372
Drug: Albuterol with
Normalized name: albuterol with CFC 90 mcg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol with 9 mg/kg caffeine
Study: 10525070
Drug: Chlorprothixene administered
Normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorprothixene administered intravenously
Study: 10525070
Drug: Chlorprothixene administered
Normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorprothixene administered orally
Study: 7551370
Drug: Y-24180 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-24180 (20 mg twice a day)
Study: 233160
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly)
Study: 26338891
Drug: High-Fructose Corn
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Fructose Corn Syrup (HFCS55)
Study: 16525572
Drug: Ximelagatran plus
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran plus ASA (36 mg and 72 mg)
Study: 16525572
Drug: Ximelagatran plus
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran plus ASA (72 mg)
Study: 14514744
Drug: Monthly Qa
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Qa plus standard surveillance (dynamic venous pressure and physical examination)
Study: 14514744
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (monthly Qa plus standard surveillance)
Study: 14514744
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) therapy at baseline
Study: 9048387
Drug: General endotracheal
Approvals — FDA: no, EMA: no, PMDA: no
Description: General endotracheal anesthesia with epidural augmentation (Group II)
Study: 7861794
Drug: DUI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DUI treatment program
Study: 998633
Drug: Filtered intravenous
Normalized name: FILTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered intravenous solutions
Study: 998633
Drug: Unfiltered intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfiltered intravenous solutions (Control)
Study: 28314326
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy (with maintenance)
Study: 25676422
Drug: Imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800 mg and IM 400 mg plus interferon α (IFN)
Study: 17969467
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (0.03% BAC) after extended wakefulness (18-21 hours awake)
Study: 17969467
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (0.03% BAC) in a non-sleep-deprived state
Study: 17969467
Drug: High-dose alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcohol (0.05% BAC) in a rested state
Study: 15155300
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam 2 mg, fentanyl 10 micro g
Study: 15155300
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 micro g
Study: 15155300
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intrathecal midazolam and fentanyl
Study: 9174307
Drug: Patient-controlled propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-controlled propofol sedation (PCS) combined with a basal infusion of propofol (n = 15)
Study: 9174307
Drug: Neurolept analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurolept analgesia using an initial bolus dose of fentanyl (0.7 microg/kg) and droperidol (0.04 mg/kg) followed by a fentanyl infusion (n = 15)
Study: 1532586
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment (oral ethinylestradiol, 150 micrograms daily + intramuscular polyestradiol phosphate, 80 mg/mo)
Study: 29331663
Drug: Oxaliplatin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (200 mg/M2)
Study: 26769788
Drug: e‐assessed postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐assessed postoperative recovery follow‐up daily for 14 days via smartphone app including the Swedish web‐version of Quality of Recovery (SwQoR)
Study: 22257543
Drug: EC‐MPS 1,440
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 1,440 mg/d with reduced tacrolimus (n = 46)
Study: 22257543
Drug: EC‐MPS 720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 720 mg/d with unchanged tacrolimus (n = 48)
Study: 22257543
Drug: EC‐MPS 1,440
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 1,440 mg/d
Study: 22257543
Drug: EC‐MPS 720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 720 mg/d
Study: 15811735
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide 500 mg 1 hour preoperatively followed by 250 mg every 6 hours
Study: 15811735
Drug: Topical brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brinzolamide 1% 1 drop every 12 hours starting immediately after speculum removal
Study: 15811735
Drug: No ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ocular hypotensive medication (Control group)
Study: 11966940
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation CLOtest
Study: 7620694
Drug: Vagimid 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagimid 500 tablets (500 mg metronidazole)
Study: 7620694
Drug: Vagimid vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagimid vaginal tablets (100 mg metronidazole)
Study: 7399805
Drug: Husband participation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Husband participation in all treatment sessions